Sareum today announces that Sierra Oncology (a subsidiary of GSK) has completed the return of the Clinical Study Reports and other associated documents and data related to SRA737 to Sareum’s co-development partner, the CRT Pioneer Fund LP (CPF). Sareum is entitled to a 27.5% share of any commercialisation revenues from SRA737. Sareum is evaluating next steps with CPF and will provide further updates as appropriate.
SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor ....
